Form 4: Moderna President Hoge Reports Share Transactions
Statement of Changes in Beneficial Ownership
Moderna President Stephen Hoge reported the conversion of restricted stock units into common stock and subsequent tax-related share disposals, alongside new equity awards.
Summary
- Stephen Hoge, President of Moderna, Inc., reported multiple transactions involving Moderna common stock and derivative securities.
- On February 27, 2026, Hoge acquired a total of 39,830 shares of common stock through the conversion of restricted stock units (RSUs).
- Concurrently, Hoge disposed of a total of 19,260 shares of common stock at a price of $51.71 per share to satisfy tax withholding obligations related to the RSU vests.
- Following these transactions, Hoge directly beneficially owns 1,477,997 shares of common stock.
- Indirect beneficial ownership includes 4,116 shares via Valhalla, LLC, and 151,933 shares via a trust for his spouse and children, for which he disclaims Section 16 beneficial ownership except for pecuniary interest.
- On March 1, 2026, Hoge was granted 125,466 stock options with an exercise price of $53.57, vesting 25% on March 1, 2027, with the remainder in twelve equal quarterly installments.
- Also on March 1, 2026, Hoge was granted 165,230 restricted stock units, vesting 25% on March 1, 2027, with the remainder in twelve equal quarterly installments.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a routine disclosure of executive compensation vesting and new grants, which is generally positive for executive alignment but does not provide new operational or financial insights.
Positives
- Acquisition of 39,830 common shares through RSU conversions indicates the vesting of previously granted equity compensation.
- The grant of 125,466 stock options and 165,230 restricted stock units on March 1, 2026, demonstrates continued equity-based compensation and aligns executive interests with long-term company performance.
Negatives
- Disposal of 19,260 shares to cover tax obligations, while a standard practice for RSU vesting, represents a reduction in direct shareholding.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that equity compensation, including RSUs and stock options, is a common practice in the biotechnology and pharmaceutical industry to attract and retain top executive talent, aligning their interests with long-term company performance.
Related Party Transactions
- Indirect ownership of 151,933 common shares by a trust for the benefit of Dr. Hoge's spouse and children, with his spouse as a trustee. The reporting person disclaims Section 16 beneficial ownership except to the extent of his pecuniary interest.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive equity holdings and compensation structure. The sale of shares for tax purposes is a routine event and not indicative of a change in sentiment. The new grants align executive interests with long-term company performance.
Key Dates
| Date | Description |
|---|---|
| 2023-03-01 | 25% of a restricted stock unit award vested, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2024-02-28 | 25% of a restricted stock unit award vested, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2025-02-27 | 25% of a restricted stock unit award vested, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2026-02-27 | Date of multiple RSU conversions into common stock and subsequent tax-related share disposals. |
| 2026-03-01 | Date of vesting for a restricted stock unit award (25% vested), and the grant date for new stock options and restricted stock units. |
| 2026-03-03 | Filing date of the Statement of Changes in Beneficial Ownership. |
| 2027-03-01 | Date when 25% of the newly granted stock options and restricted stock units will vest and become exercisable, with the remainder vesting in twelve equal quarterly installments thereafter. |
| 2036-03-01 | Expiration date for the newly granted stock options. |
Keywords
Moderna, MRNA, Stephen Hoge, SEC Form 4, beneficial ownership, restricted stock units, stock options, equity compensation, insider transactions
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.